Safety and Efficacy of Grazoprevir/elbasvir in the Treatment of Acute Hepatitis C in Hemodialysis Patients

Overview

Journal J Med Virol

Specialty Microbiology

Date 2021 Oct 2

PMID 34599755

Citations 3

Authors

Qinghua Ji

Xudong Chu

Yugui Zhou

Xuan Liu

Wei Zhao

Wei Ye

Affiliations

Soon will be listed here.

Abstract

Treatment of hepatitis C virus (HCV) infection with direct-acting antiviral agents (DAAs) in hemodialysis patients requires extensive consideration. At present, studies regarding DAAs for acute HCV infection in such patients are limited. The present study aims to evaluate the efficacy and safety of grazoprevir (GZR) plus elbasvir (EBR) treatment in acute hepatitis C (AHC) patients undergoing hemodialysis. Patients undergoing hemodialysis who had a nosocomial acute HCV infection were enrolled. All patients received GZR 100 mg/EBR 50 mg once daily for 12 weeks and were followed up for 12 weeks. Serum alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and HCV RNA levels were monitored during treatment and follow-up periods. Sustained virologic response at 12 weeks after treatment cessation and treatment-emergent adverse events (AEs) were assessed. A total of 68 AHC patients were enrolled. All patients were infected with HCV genotype 1b and achieved SVR12. Decreasing ALT, AST, and TBIL were observed over time in the first 4 weeks and became steady thereafter. Forty-eight (70.59%) patients reported at least one AEs. The most common AEs were fatigue, headache, and nausea. Two AHC patients discontinued treatment due to serious but drug-unrelated AEs. In conclusion, GZR/EBR has a high efficacy and safety profile in hemodialysis-dependent patients with genotype 1b AHC.

Citing Articles

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD.

Balk E, Adam G, Jadoul M, Martin P, Gordon C Kidney Int Rep. 2023; 8(2):240-253.

PMID: 36815114 PMC: 9939364. DOI: 10.1016/j.ekir.2022.11.008.

Acute hepatitis C virus infection: clinical update and remaining challenges.

Liu C, Kao J Clin Mol Hepatol. 2023; 29(3):623-642.

PMID: 36800699 PMC: 10366792. DOI: 10.3350/cmh.2022.0349.

Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.

Ji Q, Chu X, Zhou Y, Liu X, Zhao W, Ye W J Med Virol. 2021; 94(2):675-682.

PMID: 34599755 PMC: 9298284. DOI: 10.1002/jmv.27374.

References

Netski D, Mosbruger T, Depla E, Maertens G, Ray S, Hamilton R . Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis. 2005; 41(5):667-75. DOI: 10.1086/432478. View

Roth D, Nelson D, Bruchfeld A, Liapakis A, Silva M, Monsour Jr H . Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015; 386(10003):1537-45. DOI: 10.1016/S0140-6736(15)00349-9. View

Espinosa M, Martin-Malo A, Alvarez de Lara M, Gonzalez R, Rodriguez M, Aljama P . Natural history of acute HCV infection in hemodialysis patients. Clin Nephrol. 2002; 58(2):143-50. DOI: 10.5414/cnp58143. View

Deterding K, Spinner C, Schott E, Welzel T, Gerken G, Klinker H . Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis. 2016; 17(2):215-222. DOI: 10.1016/S1473-3099(16)30408-X. View

Bethea E, Chen Q, Hur C, Chung R, Chhatwal J . Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology. 2017; 67(3):837-846. PMC: 5826841. DOI: 10.1002/hep.29611. View

Wigneswaran J, Van Wyck D, Pegues D, Gholam P, Nissenson A . Hepatitis C virus infection in patients with end-stage renal disease. Hemodial Int. 2018; 22(3):297-307. DOI: 10.1111/hdi.12672. View

Preiksaitis J, Cockfield S, Fenton J, Burton N, Chui L . Serologic responses to hepatitis C virus in solid organ transplant recipients. Transplantation. 1998; 64(12):1775-80. DOI: 10.1097/00007890-199712270-00026. View

Naggie S, Marks K, Hughes M, Fierer D, MacBrayne C, Kim A . Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. Clin Infect Dis. 2017; 64(8):1035-1042. PMC: 5850409. DOI: 10.1093/cid/cix025. View

Ascione A, De Luca M, Tartaglione M, Lampasi F, Di Costanzo G, Lanza A . Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2009; 138(1):116-22. DOI: 10.1053/j.gastro.2009.10.005. View

10.

El Sayed A, Barbati Z, Turner S, Foster A, Morey T, Dieterich D . Sofosbuvir in the treatment of early HCV infection in HIV-infected men. HIV Clin Trials. 2017; 18(2):60-66. DOI: 10.1080/15284336.2017.1280594. View

11.

DAmbrosio R, Degasperi E, Colombo M, Aghemo A . Direct-acting antivirals: the endgame for hepatitis C?. Curr Opin Virol. 2017; 24:31-37. DOI: 10.1016/j.coviro.2017.03.017. View

12.

Goel A, Bhadauria D, Kaul A, Verma A, Tiwari P, Rungta S . Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir. Nephrol Dial Transplant. 2020; 36(10):1867-1871. DOI: 10.1093/ndt/gfaa187. View

13.

Rockstroh J, Bhagani S, Hyland R, Yun C, Dvory-Sobol H, Zheng W . Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2017; 2(5):347-353. DOI: 10.1016/S2468-1253(17)30003-1. View

14.

Al-Rabadi L, Box T, Singhania G, Al-Marji C, Agarwal A, Hall I . Rationale for treatment of hepatitis C virus infection in end-stage renal disease patients who are not kidney transplant candidates. Hemodial Int. 2018; 22 Suppl 1:S45-S52. DOI: 10.1111/hdi.12656. View

15.

. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018; 69(2):461-511. DOI: 10.1016/j.jhep.2018.03.026. View

16.

Alric L, Ollivier-Hourmand I, Berard E, Hillaire S, Guillaume M, Vallet-Pichard A . Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. Kidney Int. 2018; 94(1):206-213. DOI: 10.1016/j.kint.2018.02.019. View

17.

Sarrazin C, Wedemeyer H, Cloherty G, Cohen D, Chevaliez S, Herman C . Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. J Virol Methods. 2014; 214:29-32. DOI: 10.1016/j.jviromet.2014.11.027. View

18.

Pockros P, Reddy K, Mantry P, Cohen E, Bennett M, Sulkowski M . Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology. 2016; 150(7):1590-1598. DOI: 10.1053/j.gastro.2016.02.078. View

19.

Ji Q, Chu X, Zhou Y, Liu X, Zhao W, Ye W . Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients. J Med Virol. 2021; 94(2):675-682. PMC: 9298284. DOI: 10.1002/jmv.27374. View

20.

. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011). 2019; 8(3):91-165. PMC: 6336217. DOI: 10.1016/j.kisu.2018.06.001. View